keyword
MENU ▼
Read by QxMD icon Read
search

human papillomavirus vaccination

keyword
https://www.readbyqxmd.com/read/28821519/ten-year-follow-up-of-human-papillomavirus-vaccine-efficacy-against-the-most-stringent-cervical-neoplasia-end-point-registry-based-follow-up-of-three-cohorts-from-randomized-trials
#1
Matti Lehtinen, Camilla Lagheden, Tapio Luostarinen, Tiina Eriksson, Dan Apter, Katja Harjula, Marjo Kuortti, Kari Natunen, Johanna Palmroth, Tiina Petäjä, Eero Pukkala, Mari Siitari-Mattila, Frank Struyf, Pekka Nieminen, Jorma Paavonen, Gary Dubin, Joakim Dillner
OBJECTIVE: Due to long lag time between infection/cancer diagnoses human papillomavirus (HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end-points late. Cancer registry follow-up of population-based, randomised trial cohorts of vaccinated and unvaccinated women was undertaken for the estimation of VE against cervical intraepithelial neoplasia grade three and invasive cancer (CIN3+). METHODS: We report interim results with 98 561 person years of Finnish Cancer Registry -based follow-up of individually and/or cluster randomised cohorts of HPV-16/18 vaccinated and unvaccinated adolescent women enrolled in June 2003/2005, and between May 2004 and April 2005, respectively...
August 18, 2017: BMJ Open
https://www.readbyqxmd.com/read/28820433/targeting-persistent-human-papillomavirus-infection
#2
REVIEW
Srinidhi Shanmugasundaram, Jianxin You
While the majority of Human papillomavirus (HPV) infections are transient and cleared within a couple of years following exposure, 10-20% of infections persist latently, leading to disease progression and, ultimately, various forms of invasive cancer. Despite the clinical efficiency of recently developed multivalent prophylactic HPV vaccines, these preventive measures are not effective against pre-existing infection. Additionally, considering that the burden associated with HPV is greatest in regions with limited access to preventative vaccination, the development of effective therapies targeting persistent infection remains imperative...
August 18, 2017: Viruses
https://www.readbyqxmd.com/read/28819634/cervical-cancer-control-in-hiv-infected-women-past-present-and-future
#3
REVIEW
Rahel G Ghebre, Surbhi Grover, Melody J Xu, Linus T Chuang, Hannah Simonds
Since the initial recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an increased burden of cervical cancer was identified among human immunodeficiency virus (HIV)-positive women. Introduction of antiretroviral therapy (ART) decreased risks of opportunistic infections and improved overall survival. HIV-infected women are living longer. Introduction of the human papillomavirus (HPV) vaccine, cervical cancer screening and early diagnosis provide opportunities to reduce cervical cancer associated mortality...
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28818241/prevalence-of-modifiable-cancer-risk-factors-among-u-s-adults-aged-18-44-years
#4
Mary C White, Meredith L Shoemaker, Sohyun Park, Linda J Neff, Susan A Carlson, David R Brown, Dafna Kanny
INTRODUCTION: Carcinogen exposure and unhealthy habits acquired in young adulthood can set the stage for the development of cancer at older ages. This study measured the current prevalence of several cancer risk factors among young adults to assess opportunities to intervene to change the prevalence of these risk factors and potentially reduce cancer incidence. METHODS: Using 2015 National Health Interview Survey data (analyzed in 2016), the prevalence of potential cancer risk factors was estimated among U...
September 2017: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/28815421/knowledge-beliefs-and-attitudes-of-somali-men-in-olmsted-county-minnesota-u-s-on-the-human-papillomavirus-vaccine-and-cervical-cancer-screening-january-17-2015
#5
Uzoma Abakporo, Abdirahman Hussein, James W Begun, Tetyana Shippee
This study explores the general knowledge of Human Papillomavirus vaccine (HPV) and cervical cancer screening (CCS) among Somali men in the U.S., who are major decision-makers in Somali households. HPV infects both men and women, and causes genital warts and cervical cancer (CC). High mortality from CC persists among minorities due to low uptake of preventive tools. Eleven questions assessed general knowledge of HPV and CCS among 30 Somali male respondents. The knowledge of HPV and CCS by education level, age, and years lived in the U...
August 16, 2017: Journal of Immigrant and Minority Health
https://www.readbyqxmd.com/read/28812825/evaluating-global-health-partnerships-a-case-study-of-a-gavi-hpv-vaccine-application-process-in-uganda
#6
Carol Kamya, Jessica Shearer, Gilbert Asiimwe, Emily Carnahan, Nicole Salisbury, Peter Waiswa, Jennifer Brinkerhoff, Dai Hozumi
BACKGROUND: Global health partnerships have grown rapidly in number and scope, yet there has been less emphasis on their evaluation. Gavi, the Vaccine Alliance, is one such public-private partnership; in Gavi-eligible countries partnerships are dynamic networks of immunization actors who work together to support all stages and aspects of Gavi support. This paper describes a conceptual framework - the partnership framework - and analytic approach for evaluating the perceptions of partnerships' added value as well as the results from an application to one case in Uganda...
October 26, 2016: International Journal of Health Policy and Management
https://www.readbyqxmd.com/read/28812030/safety-of-human-papillomavirus-9-valent-vaccine-a-meta-analysis-of-randomized-trials
#7
REVIEW
Ana Paula Ferreira Costa, Ricardo Ney Oliveira Cobucci, Janine Medeiros da Silva, Paulo Henrique da Costa Lima, Paulo César Giraldo, Ana Katherine Gonçalves
Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28810358/human-papillomavirus-vaccine-information-motivation-and-behavioral-skills-among-young-adult-us-women
#8
Erika L Thompson, Cheryl A Vamos, Diane M Straub, William M Sappenfield, Ellen M Daley
This study elicited the information needs, motivations, and behavioral skills related to human papillomavirus vaccine decision-making among young adult women. Interviews were conducted with college women, aged 18-26 years, and stratified by recently vaccinated ( N = 25) and unvaccinated ( N = 25). Comparative thematic analysis using the Information, Motivation, and Behavioral Skills Model was conducted. Healthcare providers were identified as the most trusted sources for information. While unvaccinated women did not have experience receiving the vaccine, they reported the same procedural knowledge for vaccination...
October 1, 2016: Journal of Health Psychology
https://www.readbyqxmd.com/read/28807605/adjuvant-hpv-vaccination-for-anal-cancer-prevention-in-hiv-positive-men-who-have-sex-with-men-the-time-is-now
#9
Ashish A Deshmukh, Scott B Cantor, Elisabeth Fenwick, Elizabeth Y Chiao, Alan G Nyitray, Elizabeth A Stier, Stephen E Goldstone, Timothy Wilkin, Jagpreet Chhatwal
IMPORTANCE: Outcomes of treating high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, remain uncertain. Emerging evidence shows that post HSIL treatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves the effectiveness of treatment. However, no recommendations exist regarding the use of qHPV vaccine as an adjuvant form of therapy. Our objective was to determine whether post-treatment adjuvant vaccination should be adopted in HIV-infected MSM (individuals at highest risk for anal cancer) on the basis of cost-effectiveness determined using existing evidence or whether future research is needed...
August 11, 2017: Vaccine
https://www.readbyqxmd.com/read/28806926/evaluation-of-vaccination-herd-immunity-effects-for-anogenital-warts-in-a-low-coverage-setting-with-human-papillomavirus-vaccine-an-interrupted-time-series-analysis-from-2005-to-2010-using-health-insurance-data
#10
Kathrin Thöne, Johannes Horn, Rafael Mikolajczyk
BACKGROUND: Shortly after the human papillomavirus (HPV) vaccine recommendation and hence the reimbursement of vaccination costs for the respective age groups in Germany in 2007, changes in the incidence of anogenital warts (AGWs) were observed, but it was not clear at what level the incidence would stabilize and to what extent herd immunity would be present. Given the relatively low HPV vaccination coverage in Germany, we aimed to assess potential vaccination herd immunity effects in the German setting...
August 14, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28806741/risk-of-cancer-in-patients-with-genital-warts-a-nationwide-population-based-cohort-study-in-taiwan
#11
Ching-Yi Cho, Yu-Cheng Lo, Miao-Chiu Hung, Chou-Cheng Lai, Chun-Jen Chen, Keh-Gong Wu
BACKGROUND: Condyloma acuminata currently affects around 1% of sexually active adults, and its incidence is increasing. The coexistence of genital warts (GW) and certain cancers and an association between human papillomavirus (HPV) and various malignancies have been reported. Therefore, we conducted this large national study to analyze the risk of malignancies among men and women with GW in Taiwan. METHODS AND FINDINGS: Between January 2000 and December 2013, approximately 3 million patients were reported to the National Health Insurance Research Database of Taiwan...
2017: PloS One
https://www.readbyqxmd.com/read/28801303/health-care-providers-knowledge-of-hpv-vaccination-barriers-and-strategies-in-a-state-with-low-hpv-vaccine-receipt-mixed-methods-study
#12
Echo L Warner, Qian Ding, Lisa Pappas, Julia Bodson, Brynn Fowler, Ryan Mooney, Anne C Kirchhoff, Deanna Kepka
BACKGROUND: Human papillomavirus (HPV) vaccination is below national goals in the United States. Health care providers are at the forefront of improving vaccination in the United States, given their close interactions with patients and parents. OBJECTIVE: The objective of this study was to assess the associations between demographic and practice characteristics of the health care providers with the knowledge of HPV vaccination and HPV vaccine guidelines. Furthermore, our aim was to contextualize the providers' perceptions of barriers to HPV vaccination and strategies for improving vaccination in a state with low HPV vaccine receipt...
August 11, 2017: JMIR Cancer
https://www.readbyqxmd.com/read/28801154/progress-in-prophylactic-human-papillomavirus-hpv-vaccination-in-2016-a-literature-review
#13
Polona J Maver, Mario Poljak
Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate screening, it has the potential to dramatically reduce cervical cancer incidence and even eradicate it. Following extensive evaluations in clinical trials, the first decade of routine HPV vaccine use provides overwhelming evidence of the vaccines' safety and their real-life effectiveness. In 2016, further clinical trials showed high vaccine efficacy in adult women, especially those that were HPV DNA-negative at baseline, and indicated possible protection from HPV-related diseases after treatment of precancerous cervical lesions...
August 8, 2017: Vaccine
https://www.readbyqxmd.com/read/28800364/expression-optimization-of-a-cell-membrane-penetrating-human-papillomavirus-type-16-therapeutic-vaccine-candidate-in-nicotiana-benthamiana
#14
Romana J R Yanez, Renate Lamprecht, Milaid Granadillo, Brandon Weber, Isis Torrens, Edward P Rybicki, Inga I Hitzeroth
High-risk human papillomaviruses (hr-HPVs) cause cervical cancer, the fourth most common cancer in women worldwide. A HPV-16 candidate therapeutic vaccine, LALF32-51-E7, was developed by fusing a modified E7 protein to a bacterial cell-penetrating peptide (LALF): this elicited both tumour protection and regression in pre-clinical immunization studies. In the current study, we investigated the potential for producing LALF32-51-E7 in a plant expression system by evaluating the effect of subcellular localization and usage of different expression vectors and gene silencing suppressors...
2017: PloS One
https://www.readbyqxmd.com/read/28797293/health-care-providers-perceptions-of-use-and-influence-of-clinical-decision-support-reminders-qualitative-study-following-a-randomized-trial-to-improve-hpv-vaccination-rates
#15
Brian E Dixon, Monica L Kasting, Shannon Wilson, Amit Kulkarni, Gregory D Zimet, Stephen M Downs
BACKGROUND: Human Papillomavirus (HPV) leads to serious health issues and remains the most common sexually transmitted infection. Despite availability of effective vaccines, HPV vaccination rates are suboptimal. Furthermore, providers recommend the HPV vaccine less than half the time for eligible patients. Prior informatics research has demonstrated the effectiveness of computer-based clinical decision support (CDS) in changing provider behavior, especially in the area of preventative services...
August 10, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/28797277/facilitators-and-barriers-to-the-acceptance-of-human-papillomavirus-hpv-vaccination-among-adolescent-girls-a-comparison-between-mothers-and-their-adolescent-daughters-in-hong-kong
#16
Alice Yuen Loke, Ava Chiu Oi Chan, Yuen Ting Wong
BACKGROUND: The aim of this study is to examine knowledge and attitude as facilitators and barriers to the acceptance of HPV vaccination for adolescent girls by mothers and adolescent girls. METHODS: A cross-sectional survey conducted in Hong Kong in January 2010. Adolescent girls aged 12-18, together with their mothers, were recruited to complete two separate questionnaires with similar questions. RESULTS: A total of 170 mother-adolescent girl dyads were recruited...
August 10, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28796684/maternal-and-infant-outcomes-after-human-papillomavirus-vaccination-in-the-periconceptional-period-or-during-pregnancy
#17
Heather S Lipkind, Gabriela Vazquez-Benitez, James D Nordin, Paul A Romitti, Allison L Naleway, Nicola P Klein, Rulin C Hechter, Michael L Jackson, Simon J Hambidge, Grace M Lee, Lakshmi Sukumaran, Elyse O Kharbanda
OBJECTIVE: To evaluate whether quadrivalent human papillomavirus (HPV) vaccine administered during the periconceptional period or during pregnancy was associated with increased risks for adverse obstetric events, adverse birth outcomes, or selected major structural birth defects. METHODS: We conducted a retrospective, observational cohort study using administrative and health care data from the Vaccine Safety Datalink. Insured women 13-27 years old with singleton pregnancies and a live birth from January 1, 2007, through September 1, 2013, who received quadrivalent HPV vaccine during the periconceptional period (2 weeks before to 2 weeks after their last menstrual period), during pregnancy, or during both periods combined were compared with women who had a live birth during the same time period and received quadrivalent HPV vaccine 4-18 months before their last menstrual period...
August 4, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28795126/nonavalent-human-papillomavirus-vaccination-as-a-treatment-for-warts-in-an-immunosuppressed-adult
#18
Sara B Ferguson, Elisa S Gallo
No abstract text is available yet for this article.
July 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28794879/human-papillomavirus-driven-immune-deviation-challenge-and-novel-opportunity-for-immunotherapy
#19
REVIEW
Sigrun Smola, Connie Trimble, Peter L Stern
It is now recognized that the immune system can be a key component of restraint and control during the neoplastic process. Human papillomavirus (HPV)-associated cancers of the anogenital tract and oropharynx represent a significant clinical problem but there is a clear opportunity for immune targeting of the viral oncogene expression that drives cancer development. However, high-risk HPV infection of the target epithelium and the expression of the E6/E7 oncogenes can lead to early compromise of the innate immune system (loss of antigen-presenting cells) facilitating viral persistence and increased risk of cancer...
June 2017: Therapeutic Advances in Vaccines
https://www.readbyqxmd.com/read/28792475/human-papillomavirus-and-the-stroma-bidirectional-crosstalk-during-the-virus-life-cycle-and-carcinogenesis
#20
REVIEW
Megan E Spurgeon, Paul F Lambert
Human papillomaviruses (HPVs) are double-stranded DNA (dsDNA) tumor viruses that are causally associated with human cancers of the anogenital tract, skin, and oral cavity. Despite the availability of prophylactic vaccines, HPVs remain a major global health issue due to inadequate vaccine availability and vaccination coverage. The HPV life cycle is established and completed in the terminally differentiating stratified epithelia, and decades of research using in vitro organotypic raft cultures and in vivo genetically engineered mouse models have contributed to our understanding of the interactions between HPVs and the epithelium...
August 9, 2017: Viruses
keyword
keyword
113483
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"